The objective of this study is to evaluate the efficacy and safety of an active drug compared to placebo as induction therapy in subjects with moderately and severely active Crohn's disease (CD).
From 18 Years to 75 Years.
- Confirmed diagnosis of CD for at least 3 months prior to Baseline.
- Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF),
abdominal pain (AP) score.
- Evidence of mucosal inflammation based on the Simplified Endoscopic Score for Crohn's
disease (SES-CD) on an endoscopy confirmed by a central reader.
- Demonstrated an inadequate response or intolerance to any biologic therapy for
infliximab, adalimumab, certolizumab pegol, vedolizumab, and ustekinumab.
- If female, participant must meet the contraception recommendations.
- Participant with a current diagnosis of ulcerative colitis or indeterminate colitis.
- Participant not on stable doses of CD related antibiotics, oral aminosalicylates,
corticosteroids or methotrexate (MTX).
- Participant with the following ongoing known complications of CD: abscess (abdominal
or peri-anal), symptomatic bowel strictures, fulminant colitis, toxic megacolon, or
any other manifestation that might require surgery while enrolled in the study.
- Participant with ostomy or ileoanal pouch.
- Participant diagnosed with conditions that could interfere with drug absorption
including but not limited to short gut or short bowel syndrome.
- Screening laboratory and other protocol pre-specified analyses show abnormal results.